ENHANCED MEDICAL TREATMENTS RESULTING FROM CHEMICAL IDENTIFICATION OF CALCIUM INFLUX FACTOR, IDENTITY WITH THE FACTOR ACTIVATING PHOSPHOLIPOLYSIS AND PRECIPITATING SUDDEN DEATH DURING MYOCARDIAL INFARCTION, AND DETERMINATION OF SIMILAR ACTIVATING MECHANISMS IN MULTIPLE CELL TYPES THROUGH DISINHIBITION OF CALCIUM-INDEPENDENT PHOSPHOLIPASE A2beta

a technology of calcium influx factor and chemical identification, applied in the field of biomarker screening, can solve the problems of serious life-threatening, poorly understood biochemical mechanisms underlying metabolic syndrome and its end-organ sequelae, and inability to detect the presence of a single molecule in the body,

Inactive Publication Date: 2007-11-15
WASHINGTON UNIV IN SAINT LOUIS
View PDF1 Cites 5 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Despite the enormous proportions of this public health problem, the biochemical mechanisms underlying the metabolic syndrome and its end-organ sequelae are poorly understood.
However, when glucose builds up in the blood instead of going into cells (e.g., insulin resistance), it can cause serious life threatening problems which results in type 2 diabetes.
In this condition the body does not

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • ENHANCED MEDICAL TREATMENTS RESULTING FROM CHEMICAL IDENTIFICATION OF CALCIUM INFLUX FACTOR, IDENTITY WITH THE FACTOR ACTIVATING PHOSPHOLIPOLYSIS AND PRECIPITATING SUDDEN DEATH DURING MYOCARDIAL INFARCTION, AND DETERMINATION OF SIMILAR ACTIVATING MECHANISMS IN MULTIPLE CELL TYPES THROUGH DISINHIBITION OF CALCIUM-INDEPENDENT PHOSPHOLIPASE A2beta
  • ENHANCED MEDICAL TREATMENTS RESULTING FROM CHEMICAL IDENTIFICATION OF CALCIUM INFLUX FACTOR, IDENTITY WITH THE FACTOR ACTIVATING PHOSPHOLIPOLYSIS AND PRECIPITATING SUDDEN DEATH DURING MYOCARDIAL INFARCTION, AND DETERMINATION OF SIMILAR ACTIVATING MECHANISMS IN MULTIPLE CELL TYPES THROUGH DISINHIBITION OF CALCIUM-INDEPENDENT PHOSPHOLIPASE A2beta
  • ENHANCED MEDICAL TREATMENTS RESULTING FROM CHEMICAL IDENTIFICATION OF CALCIUM INFLUX FACTOR, IDENTITY WITH THE FACTOR ACTIVATING PHOSPHOLIPOLYSIS AND PRECIPITATING SUDDEN DEATH DURING MYOCARDIAL INFARCTION, AND DETERMINATION OF SIMILAR ACTIVATING MECHANISMS IN MULTIPLE CELL TYPES THROUGH DISINHIBITION OF CALCIUM-INDEPENDENT PHOSPHOLIPASE A2beta

Examples

Experimental program
Comparison scheme
Effect test

example

[0080] Materials—[1-14C]-palmitoyl-CoA and [1-14C]-oleoyl-CoA, and 1-palmitoyl-2-[1-14C]-oleoyl-sn-glycero-3-phosphocholine were obtained from Perkin-Elmer. [1-14C]-Arachidonoyl-CoA, [1-14C]-myristoyl-CoA, [1-14C]-stearoyl-CoA, and [methyl-14C] human albumin were obtained from American Radiolabeled Chemicals. 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC) and 1,2-dioleoyl-sn-glycero-3-[phospho-L-serine] (DOPS) were purchased from Avanti Polar Lipids. 2-decanoyl-1-(O-(11-(4,4-difluoro-5,7-dimethyl-4-bora-3α,4α-diaza-s-indacene-3-propionyl)amino)undecyl)-sn-glycero3phosphocholine (BODIPY-PC) was purchased from Invitogen. High purity bovine calmodulin was obtained from Calbiochem. Most other materials were obtained from either Sigma or Fisher Scientific. BEL was purchased from Cayman Chemical and separated into individual enantiomers as described previously (62).

[0081] Expression and Affinity Purification of iPLA2β(His)6 from Sf9 Cells—Following infection of 3×100 ml cultures...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
Concentrationaaaaaaaaaa
Contentaaaaaaaaaa
Capacitoraaaaaaaaaa
Login to view more

Abstract

A method for treating a mammal comprises administering at least one of a gene, enzyme and pharmaceutical which modulates the concentration of iPLA2β through transcriptional and/or translational regulation or effectively modulate the inhibition of iPLA2β through calmodulin or derivatives thereof.

Description

CROSS-REFERENCE TO RELATED APPLICATIONS [0001] This application claims the priority of U.S. Provisional Patent Application Ser. No. 60 / 723,685 filed Oct. 5, 2005, which is hereby incorporated by referenced in its entirety.STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH AND DEVELOPMENT [0002] This invention was made under contracts NIH 5P01HL57278 and NIH 5R01HL41250. The government has certain rights in the invention.BACKGROUND OF THE INVENTION [0003] This invention relates generally to biomarker screening and more particularly to identifying new targets for pharmacological inhibition. [0004] This invention also relates generally to analytical (assays) methods for identifying compounds useful for promoting health in living mammalian systems. In particular this invention relates to assays and analytical tools for monitoring health in living mammals. [0005] The function of complex living biological organisms relies on the meticulous control of cellular activity, including close regul...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K38/43A61K31/7052A61P3/04A61P9/12A61P9/00A61K38/16
CPCA61K31/7052A61P3/04A61P9/00A61P9/12
Inventor GROSS, RICHARD W.JENKINS, CHRISTOPHER
Owner WASHINGTON UNIV IN SAINT LOUIS
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap